The key point is that Procter \u0026 Gamble is acquiring the dietary supplement brand Thorne for $3.8 billion.

In an interview on "Street Talk," Procter \u0026 Gamble CEO Shailesh Jejurikar stated that the acquisition aims to strengthen the company\u2019s health business. The deal is set to be officially announced on Tuesday, marking a significant step in Procter \u0026 Gamble\u2019s expansion within the healthcare sector.

Options for getting started

The consumer goods giant already owns several dietary supplement brands, including Metamucil, Align probiotics, and New Chapter vitamins. These are all grouped under the company\u2019s Health Care division, which also includes brands like Oral-B and Vicks. Jejurikar told host Sara Eisen, "We are very bullish on this asset. Thorne has a mature operating system and a long history as a brand."

Insights into the acquisition rationale

Founded in 1984, Thorne went public in late 2021 with a valuation of $525 million. In 2023, private equity firm L Catterton took the company private in a $680 million deal. Thorne has disclosed that its full-year 2025 revenue surpassed $500 million. Thorne CEO Colin Watts said earlier this year that the brand could grow into a billion-dollar revenue brand over the next few years.

Target audience and market trends

A majority of Thorne\u2019s revenue comes from consumers under the age of 40, and its direct-to-consumer (DTC) business is growing rapidly. In recent years, interest in vitamins and dietary supplements has surged, with consumers using these products to improve sleep, boost energy, and manage overall health. The "Make America Healthy Again" movement, championed by Health and Human Services Secretary Robert F. Kennedy Jr., has also strongly promoted dietary supplements. Kennedy himself has admitted that he takes so many vitamins that he struggles to keep track.

Strategic direction and market reaction

Procter \u0026 Gamble is not the first major consumer goods company to seize this trend by acquiring a popular new-age brand. Earlier this year, Unilever acquired the gummy supplement brand G\u00fcrns. While Thorne represents a small part of Procter \u0026 Gamble\u2019s vast product portfolio, this deal clearly reflects the company\u2019s strategy: investing in premium brands that align with current trends and appeal to younger consumers. In its latest quarterly earnings report, Procter \u0026 Gamble posted flat sales volumes that missed revenue expectations, with the Health Care division showing the weakest performance. On Tuesday afternoon, Procter \u0026 Gamble\u2019s stock edged up less than 1%.